Emanuele Zucca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5039728/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Revised Response Criteria for Malignant Lymphoma. Journal of Clinical Oncology, 2007, 25, 579-586.	1.6	4,061
2	Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. Journal of Clinical Oncology, 2014, 32, 3059-3067.	1.6	3,729
3	Follicular Lymphoma International Prognostic Index. Blood, 2004, 104, 1258-1265.	1.4	1,552
4	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 2014, 32, 3048-3058.	1.6	1,269
5	Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. Journal of Clinical Oncology, 2005, 23, 5034-5043.	1.6	729
6	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, The, 2009, 374, 1512-1520.	13.7	588
7	Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood, 2004, 103, 4416-4423.	1.4	531
8	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	1.4	512
9	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology,the, 2016, 3, e217-e227.	4.6	442
10	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood, 2003, 102, 2741-2745.	1.4	391
11	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematology,the, 2016, 3, e196-e204.	4.6	344
12	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti– <i>Helicobacter Pylori</i> Therapy. Journal of Clinical Oncology, 2005, 23, 1979-1983.	1.6	265
13	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.	4.6	258
14	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clinical Cancer Research, 2015, 21, 1628-1638.	7.0	237
15	The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood, 2009, 113, 4918-4921.	1.4	232
16	Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Human Pathology, 2000, 31, 263-268.	2.0	227
17	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood, 2018, 131, 2413-2425.	1.4	223
18	The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood, 2016, 127, 2082-2092	1.4	219

#	Article	IF	CITATIONS
19	Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98. Journal of Clinical Oncology, 2010, 28, 4480-4484.	1.6	218
20	Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 17-29.	1.2	197
21	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 2011, 117, 1595-1604.	1.4	173
22	Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). Journal of Clinical Oncology, 2015, 33, 2523-2529.	1.6	157
23	[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. Journal of Clinical Oncology, 2014, 32, 1769-1775.	1.6	149
24	A MALT lymphoma prognostic index. Blood, 2017, 130, 1409-1417.	1.4	149
25	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. Journal of Clinical Oncology, 2017, 35, 1905-1912.	1.6	143
26	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood, 2015, 126, 950-956.	1.4	138
27	Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Annals of Oncology, 2009, 20, 1086-1093.	1.2	130
28	Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood, 2002, 99, 2541-2544.	1.4	110
29	Histologic transformation in marginal zone lymphomas. Annals of Oncology, 2015, 26, 2329-2335.	1.2	104
30	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood, 2013, 122, 2683-2693.	1.4	98
31	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical Cancer Research, 2018, 24, 120-129.	7.0	92
32	Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas. Clinical Cancer Research, 2014, 20, 5207-5216.	7.0	91
33	Incidence, risk factors and outcome of histological transformation in follicular lymphoma. British Journal of Haematology, 2012, 157, 188-196.	2.5	89
34	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. Journal of Clinical Oncology, 2017, 35, 552-560.	1.6	87
35	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood, 2020, 135, 1859-1869.	1.4	86
36	Gela histological scoring system for postâ€ŧreatment biopsies of patients with gastric <scp>MALT</scp> lymphoma is feasible and reliable in routine practice. British Journal of Haematology, 2013, 160, 47-52.	2.5	79

Emanuele Zucca

#	Article	IF	CITATIONS
37	Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Annals of Oncology, 2013, 24, 1344-1351.	1.2	75
38	Genome wide DNAâ€profiling of HIVâ€related Bâ€cell lymphomas. British Journal of Haematology, 2010, 148, 245-255.	2.5	70
39	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Annals of Oncology, 2011, 22, 689-695.	1.2	64
40	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood, 2018, 132, 179-186.	1.4	63
41	Chlorambucil <i>versus</i> observation after antiâ€ <i>Helicobacter</i> therapy in gastric MALT lymphomas: results of the international randomised LYO3 trial. British Journal of Haematology, 2009, 144, 367-375.	2.5	60
42	Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treatment Reviews, 2014, 40, 1080-1088.	7.7	58
43	Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood, 2001, 98, 781-786.	1.4	55
44	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. Haematologica, 2019, 104, e558-e561.	3.5	55
45	Rituximab in primary central nervous system lymphoma—A systematic review and metaâ€analysis. Hematological Oncology, 2019, 37, 548-557.	1.7	54
46	MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e110-e121.	4.6	54
47	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood, 2015, 125, 1922-1931.	1.4	53
48	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix). BMC Cancer, 2016, 16, 282.	2.6	53
49	Marginal-Zone Lymphomas. New England Journal of Medicine, 2022, 386, 568-581.	27.0	53
50	Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. Journal of Clinical Oncology, 2022, 40, 2352-2360.	1.6	53
51	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Oncologist, 2015, 20, 1149-1153.	3.7	52
52	Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. Haematologica, 2013, 98, 357-363.	3.5	51
53	Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. Journal of Clinical Oncology, 2016, 34, 495-500.	1.6	49
54	Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 2022, 139, 732-747.	1.4	49

Emanuele Zucca

#	Article	IF	CITATIONS
55	A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT) Tj ETQq1 1 Oncology, 2016, 34, 177-183.	0.784314 1.7	ł rgBT /Over 48
56	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Advances, 2020, 4, 1082-1092.	5.2	47
57	Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica, 2000, 85, 147-53.	3.5	47
58	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36, 1870-1878.	7.2	47
59	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood, 2019, 134, 353-362.	1.4	45
60	The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. Clinical Cancer Research, 2019, 25, 5167-5176.	7.0	43
61	Genomic profiles of MALT lymphomas: variability across anatomical sites. Haematologica, 2011, 96, 1064-1066.	3.5	42
62	Preclinical evaluation of the <scp>BET</scp> bromodomain inhibitor <scp>BAY</scp> 1238097 for the treatment of lymphoma. British Journal of Haematology, 2017, 178, 936-948.	2.5	42
63	Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALTâ€ŧype gastric lymphoma B cells have undergone an antigen selection process. British Journal of Haematology, 1997, 97, 830-836.	2.5	41
64	Low prevalence ofChlamydia psittaciin ocular adnexal lymphomas from Cuban patients. Leukemia and Lymphoma, 2007, 48, 104-108.	1.3	41
65	<scp><i>MYD88</i></scp> somatic mutations in <scp>MALT</scp> lymphomas. British Journal of Haematology, 2012, 158, 662-664.	2.5	41
66	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. British Journal of Haematology, 2018, 183, 755-765.	2.5	41
67	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Advances, 2021, 5, 2375-2384.	5.2	40
68	MALT lymphomas: pathogenesis can drive treatment. Oncology, 2011, 25, 1134-42, 1147.	0.5	40
69	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Advances, 2020, 4, 4124-4135.	5.2	37
70	Recent advances in understanding the biology of marginal zone lymphoma. F1000Research, 2018, 7, 406.	1.6	35
71	Patterns of survival of follicular lymphomas at a single institution through three decades. Leukemia and Lymphoma, 2010, 51, 1028-1034.	1.3	33
72	Life expectancy of young adults with follicular lymphoma. Annals of Oncology, 2015, 26, 2317-2322.	1.2	31

#	Article	IF	CITATIONS
73	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 42-49.	0.8	31
74	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica, 2020, 105, 2592-2597.	3.5	29
75	Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of <i>CDKN1A</i> expression levels in mediating their anti-tumor response. Oncotarget, 2015, 6, 5059-5071.	1.8	29
76	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica, 2019, 104, 1633-1639.	3.5	28
77	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Advances, 2020, 4, 819-829.	5.2	28
78	Management of the Marginal Zone Lymphomas. Cancer Treatment and Research, 2015, 165, 227-249.	0.5	27
79	Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. Haematologica, 2020, 105, 2584-2591.	3.5	27
80	Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Annals of Oncology, 2016, 27, 1123-1128.	1.2	26
81	Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?. Therapeutic Advances in Hematology, 2016, 7, 94-107.	2.5	26
82	Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong <i>in vivo</i> antitumor activity in lymphoma. Oncotarget, 2016, 7, 58142-58147.	1.8	25
83	Hepatitis C virus-associated B-cell non-Hodgkin lymphomas. Hematology American Society of Hematology Education Program, 2014, 2014, 590-598.	2.5	22
84	The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15â€ŧCML workshop on ctDNA. Hematological Oncology, 2020, 38, 34-37.	1.7	22
85	Marginal zone lymphoma: present status and future perspectives. Haematologica, 2022, 107, 35-43.	3.5	22
86	Report of the 6th International Workshop on PET in lymphoma. Leukemia and Lymphoma, 2017, 58, 2298-2303.	1.3	21
87	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. British Journal of Haematology, 2010, 151, 435-439.	2.5	20
88	Prognostic models for primary mediastinal (thymic) Bâ€cell lymphoma derived from 18â€ <scp>FDG PET</scp> / <scp>CT</scp> quantitative parameters in the International Extranodal Lymphoma Study Group (<scp>IELSG</scp>) 26 study. British Journal of Haematology, 2017, 178, 588-591.	2.5	20
89	Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. Annals of Oncology, 2018, 29, 332-340.	1.2	20
90	Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Annals of Oncology, 2018, 29, 1120-1129.	1.2	18

#	Article	IF	CITATIONS
91	Toward New Treatments for Mantle-Cell Lymphoma?. New England Journal of Medicine, 2013, 369, 571-572.	27.0	17
92	Hepatitis C virus and GBVâ€C virus prevalence among patients with Bâ€cell lymphoma in different European regions: a caseâ€control study of the International Extranodal Lymphoma Study Group. Hematological Oncology, 2012, 30, 137-142.	1.7	16
93	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers, 2019, 11, 775.	3.7	14
94	Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1334-1344.	6.4	14
95	Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large Bâ€cell lymphoma: postâ€hoc analysis from the SAKK38/07 clinical trial. Hematological Oncology, 2020, 38, 715-725.	1.7	14
96	Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapyâ€free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). British Journal of Haematology, 2021, 192, 1031-1034.	2.5	14
97	Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. British Journal of Haematology, 2020, 189, 707-717.	2.5	13
98	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with Râ€CHOP14: A SAKK 38/07 trial postâ€hoc analysis. Hematological Oncology, 2022, 40, 12-22.	1.7	13
99	Single and combined BTK and PI3KÎ′ inhibition with acalabrutinib and ACPâ€319 in preâ€clinical models of aggressive lymphomas. British Journal of Haematology, 2019, 187, 595-601.	2.5	12
100	Absence of <i>NOTCH1</i> gene mutations in MALT lymphomas. British Journal of Haematology, 2012, 157, 382-384.	2.5	11
101	Follicular lymphoma: Stateâ€ofâ€theâ€art ICML workshop in Lugano 2015. Hematological Oncology, 2017, 35, 397-407.	1.7	11
102	Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 71-76.	1.3	10
103	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. Blood Advances, 2021, 5, 2467-2480.	5.2	10
104	Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. Blood Advances, 2021, 5, 4674-4685.	5.2	10
105	Diagnosis and treatment of follicular lymphoma. Swiss Medical Weekly, 2011, 141, w13247.	1.6	10
106	Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Advances, 2020, 4, 5951-5957.	5.2	9
107	Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial. British Journal of Haematology, 2020, 190, e258-e261.	2.5	9
108	THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA "TRANSFORMED―BY RITUXIMAB: THE ARISTO	TLE 1.7	8

108 STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE. Hematological Oncology, 2017, 35, 115-116.

#	Article	IF	CITATIONS
109	FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. Hematological Oncology, 2019, 37, 224-225.	1.7	7
110	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. Cancers, 2022, 14, 1018.	3.7	7
111	METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA Hematological Oncology, 2017, 35, 60-61.	1.7	5
112	PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPYâ€FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK) Hematological Oncology, 2019, 37, 111-112.	1.7	5
113	A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II TRIAL EVALUATING SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB ANDOBINUTUZUMAB IN RICHTER TRANSFORMATION FROM CLL. Hematological Oncology, 2019, 37, 557-558.	1.7	5
114	Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. Hematological Oncology, 2021, 39, 196-204.	1.7	5
115	SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, e2016062.	1.3	4
116	Populationâ€based outcome analysis of diffuse large Bâ€cell lymphoma in people living with HIV infection and competent individuals. Hematological Oncology, 2018, 36, 757-764.	1.7	4
117	SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Advances, 2022, 6, 3911-3920.	5.2	4
118	Novel acquisitions on biology and management of transformed follicular lymphoma. Hematological Oncology, 2018, 36, 617-623.	1.7	3
119	Radiomics in Malignant Lymphomas. , 0, , 71-82.		3
120	Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials. Leukemia and Lymphoma, 2022, 63, 1544-1555.	1.3	3
121	The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. Exploration of Targeted Anti-tumor Therapy, 2021, 2, 586-601.	0.8	3
122	<i>>D</i> _{max} : A simple and reliable PET/CTâ€derived new biomarker of lymphoma outcome?. Hematological Oncology, 2022, 40, 843-845.	1.7	3
123	A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone Bâ€cell lymphomas. Hematological Oncology, 2021, 39, 60-65.	1.7	2
124	Use of epirubicin to treat diffuse large B-cell lymphoma. Lancet Haematology,the, 2019, 6, e292-e293.	4.6	1
125	Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03. Blood, 2018, 132, 1601-1601.	1.4	1
126	A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL. Journal of Clinical Oncology, 2019, 37, TPS7575-TPS7575.	1.6	1

#	Article	IF	CITATIONS
127	Ibrutinib dose intensity in highâ€risk chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 1100-1104.	1.7	1
128	Reply to the letter to the editor â€~Survival in young adults diagnosed with follicular lymphoma' by Calvo et al Annals of Oncology, 2016, 27, 1173.	1.2	0
129	PET imaging of lymphomas. , 2021, , .		0
130	ECF can be used as adjuvant treatment for oesophagogastric adenocarcinoma: A two-institutions experience. Journal of Clinical Oncology, 2004, 22, 4251-4251.	1.6	0
131	Cost-effectiveness of shortening treatment duration based on interim PET outcome in patients with diffuse large B-cell lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	0
132	Finding a consensus on timeâ€toâ€event endpoints definitions in marginal zone lymphoma: A Delphi method. Hematological Oncology, 2022, 40, 1086-1089.	1.7	0
133	ECF can be used as adjuvant treatment for oesophagogastric adenocarcinoma: A two-institutions experience. Journal of Clinical Oncology, 2004, 22, 4251-4251.	1.6	0